Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS) has announced a virtual R&D Day scheduled for Oct. 2, 2024, at 10:00 a.m. ET. The event will focus on the company's strategic vision and the development of sabirnetug, their novel treatment for early Alzheimer's disease (AD) that targets toxic soluble amyloid beta oligomers (AβOs).

The webcast will feature Acumen's management and scientific leadership, along with external key opinion leaders including:

• Dr. Stephen Salloway, Director of the Memory and Aging Program at Butler Hospital and Professor at Brown University
• Dr. Paul Solomon, Founder of the Boston Center for Memory and investigator in the ongoing Phase 2 ALTITUDE-AD trial for sabirnetug

Participants can register for the live conference call and access the webcast through links provided. An archived version will be available on Acumen's website for at least one year.

News Market Reaction – ABOS

+3.85%

1 alert

+3.85% News Effect

On the day this news was published, ABOS gained 3.85%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the Company will host a virtual R&D Day on Wednesday, Oct. 2 at 10:00 a.m. ET. The webcast will highlight Acumen’s strategic vision, and focus on the mechanistic rationale, pre-clinical and clinical data that support further development of sabirnetug as a treatment for early AD.

Featured Speakers
Acumen management and scientific leadership will be joined by external key opinion leaders who will discuss the current treatment paradigm and unmet need in early Alzheimer’s disease, as well as the potential for sabirnetug as an innovative treatment in this indication.

• Dr. Stephen Salloway, MD, MS, the founding Director of the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, Associate Director of the Brown Center for Alzheimer’s Disease Research, and Professor of Neurology and Psychiatry at the Warren Alpert Medical School of Brown University.
  
  
• Dr. Paul Solomon, PhD, the Founder and Clinical Director of the Boston Center for Memory, professor in the Department of Neurology at Boston University School of Medicine and an investigator at Boston University's Alzheimer's Disease Center. Dr. Solomon also serves as an investigator in the ongoing Phase 2 ALTITUDE-AD trial investigating sabirnetug.
  

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.  

The webcast will be available via this link.  

An archived version of the webcast will be available for at least one year in the Investors section of the Company's website at www.acumenpharm.com.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com. 

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

FAQ

When is Acumen Pharmaceuticals (ABOS) hosting its virtual R&D Day in 2024?

Acumen Pharmaceuticals (ABOS) is hosting its virtual R&D Day on Wednesday, October 2, 2024, at 10:00 a.m. ET.

What is the focus of Acumen Pharmaceuticals' (ABOS) R&D Day presentation?

The R&D Day will focus on Acumen's strategic vision and the development of sabirnetug, their novel treatment for early Alzheimer's disease that targets toxic soluble amyloid beta oligomers (AβOs).

Who are the key speakers at Acumen Pharmaceuticals' (ABOS) R&D Day event?

Key speakers include Acumen management, scientific leadership, Dr. Stephen Salloway from Butler Hospital and Brown University, and Dr. Paul Solomon from the Boston Center for Memory and Boston University.

What is sabirnetug, the drug being developed by Acumen Pharmaceuticals (ABOS)?

Sabirnetug is Acumen's novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer's disease.

How can investors participate in Acumen Pharmaceuticals' (ABOS) R&D Day?

Investors can participate by registering for the live conference call or accessing the webcast through links provided by Acumen Pharmaceuticals.